Sign In
Buy GLP
$48.46
-0.170 (-0.350%)
At Close: Jul 29, 2026
Novo Nordisk to slash GLP-1 list prices by up to 50% in U.S. to cut costs for insured patients
08:54am, Tuesday, 24'th Feb 2026
Novo Nordisk on Tuesday said it plans to slash the monthly list prices of its popular obesity and diabetes drugs in the U.S. by up to 50% starting in 2027. The move aims to make the treatments more ac
Hims & Hers Health After The GLP-1 Collapse
08:47am, Tuesday, 24'th Feb 2026
Hims & Hers Health's revenue grew 59% to $2.35B in 2025, while adjusted EBITDA surged nearly 80% to $318M. Operating cash flow reached $300M, with $929M in liquidity, reinforcing balance sheet strengt
First Wave of Influencers with Combined Reach of Over 23 Million to Drive National Awareness Lake Oswego, Oregon--(Newsfile Corp. - February 24, 2026) - Functional Brands Inc. (NASDAQ: MEHA), a leadin
Hims & Hers Q4 Earnings Show Growth Amid GLP-1 Scrutiny
06:30am, Tuesday, 24'th Feb 2026
Hims & Hers Health delivered strong FY25 results with 59% revenue growth to $2.35B and 13% subscriber growth, but faces near-term margin pressure. Management guided FY26 revenue of $2.7–$2.9B and Ad
Eli Lilly bets on multi-dose Zepbound pen in GLP-1 retention push
09:41am, Monday, 23'rd Feb 2026
Millions of people on GLP-1 weight-loss drugs know the weekly routine by heart: a new injector pen, a new box, another reminder to refill, and one more item for the sharps bin. Eli Lilly is trying to
SureNano Science Ltd. Acquires GlucaPharm Inc., Advancing Second-Generation FDA Pathway GLP-1 Drug Development
09:00am, Monday, 23'rd Feb 2026
GlucaPharm is developing GEP44, a novel, patented peptide (similar in function to Ozempic®, Wegovy®, Mounjaro®, but with reduced risk of adverse events) discovered by researchers at Syracuse Univer
Forget Ozempic: This High‑Flying Device Maker Can Thrive No Matter Which Weight Loss Drug Wins
01:15pm, Friday, 20'th Feb 2026
Novo Nordisk's GLP-1 pill has reignited the competition in the GLP-1 space. But you can sidestep that drama by buying this surgical robotics pioneer.
Novo Nordisk's Wegovy® Pill Achieves Strong First-Month Uptake, Signaling Expanding Demand for Oral GLP-1s in Obesity
07:58am, Friday, 20'th Feb 2026
Awareness and prescribing of the Wegovy pill for weight loss surge among primary care physicians and endocrinologists following its January launch. Awareness and prescribing of the Wegovy pill for wei
Healthy Returns: FDA chief Marty Makary on compounded GLP-1s, vaccines and China
02:52pm, Thursday, 19'th Feb 2026
Makary helms the FDA in the midst of a contentious stretch for the agency, defined by massive staff and budget cuts and sweeping changes to vaccine policy.
Moonage Media Review: Clearmind's MEAI and GLP-1 - Are These the Next-Generation Treatment for Weight Loss?
01:05pm, Thursday, 19'th Feb 2026
HONG KONG, Feb. 19, 2026 /PRNewswire/ -- As the multi-billion-dollar obesity treatment market continues to search for new therapeutic approaches beyond GLP-1–based treatments, Clearmind Medicine (Na
Hims & Hers GLP-1 pill gambit backfires, accelerating crackdown on drug compounders
06:04am, Thursday, 19'th Feb 2026
Online telehealth company Hims & Hers Health , seeking growth drivers as its original sexual-health franchises matured, may have overstepped with a risky launch of weight-loss pills that drew swift bl
Flowers Foods: Dividend Cut Fears And GLP-1 Panic Are An Opportunity
04:21am, Wednesday, 18'th Feb 2026
Flowers Foods remains a Strong Buy, with deep value and recovery potential despite near-term consumer headwinds and soft 2026 guidance. FLO's robust free cash flow and solid balance sheet underpin int
CollPlant Targets New Aesthetic Market Driven by GLP-1 Weight-Loss Treatments
07:00am, Tuesday, 17'th Feb 2026
Next-generation rhCollagen-based technology aims to restore facial structure and skin quality in patients experiencing volume depletion linked to GLP-1 weight-loss therapies REHOVOT, Israel, Feb. 17,
Global Partners LP to Host Fourth-Quarter and Full-Year 2025 Financial Results Conference Call on February 27, 2026
08:30am, Thursday, 12'th Feb 2026
WALTHAM, Mass.--(BUSINESS WIRE)--Global Partners LP (NYSE: GLP) (“Global Partners” or the “Partnership”) today announced that it will release its fourth-quarter and full-year 2025 financial re
More than a third of patients on Wegovy pill are new to GLP-1 drugs, study finds
01:12pm, Wednesday, 11'th Feb 2026
Among early users of Novo Nordisk's new Wegovy weight-loss pill, 36% had no prior experience taking a GLP-1 medication, a new study from the health data firm Truveta found.
